Optimisation of one-step desolvation and scale-up of gelatine nanoparticle production

被引:25
作者
Geh, Katharina J. [1 ]
Hubert, Madlen [1 ,2 ]
Winter, Gerhard [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Pharm Pharmaceut Technol & Biopharmaceut, Butenandtstr 5-13, D-81377 Munich, Germany
[2] Umea Univ, Dept Integrat Med Biol, S-90187 Umea, Sweden
关键词
Gelatine nanoparticles; one-step desolvation; scale-up; cross-linking; AF4; RECURRENT AIRWAY-OBSTRUCTION; CROSS-LINKING; 2-STEP DESOLVATION; AFFECTED HORSES; DRUG-DELIVERY; CELL UPTAKE; TRANSGLUTAMINASE; GLUTARALDEHYDE; COLLAGEN; SYSTEM;
D O I
10.1080/02652048.2016.1228706
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Gelatine nanoparticles (GNPs) are biodegradable and biocompatible drug delivery systems with excellent clinical performances. A two-step desolvation is commonly used for their preparation, although this methodology has several shortcomings: lack of reproducibility, small scales and low yields. A straightforward and more consistent GNP preparation approach is presented here focusing on the development of a one-step desolvation with the use of a commercially available gelatine type. Controlled stirring conditions and ultrafiltration are used to achieve large-scale production of nanoparticles of up to 2.6g per batch. Particle size distributions are conserved and comparable to those determined for two-step desolvation on small scale. Additionally, a range of cross-linking agents is examined for their effectiveness in stabilising GNPs as an alternative to glutaraldehyde. Glyceraldehyde demonstrated outstanding properties, which led to high colloidal stability. This approach optimises the manufacturing process and the scale-up of the production capacity, providing a clear potential for future applications.
引用
收藏
页码:595 / 604
页数:10
相关论文
共 47 条
[1]  
Ahlers M, 2007, Nanoparticles and method for the production thereof, Patent No. [EP1793810 A1, 1793810]
[2]  
Azarmi S, 2006, J PHARM PHARM SCI, V9, P124
[3]  
Babel W., 2000, Ullmann's Encyclopedia of Industrial Chemistry
[4]   Toxicological, medical and industrial hygiene aspects of glutaraldehyde with particular reference to its biocidal use in cold sterilization procedures [J].
Ballantyne, B ;
Jordan, SL .
JOURNAL OF APPLIED TOXICOLOGY, 2001, 21 (02) :131-151
[5]   Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles [J].
Bootz, A ;
Vogel, V ;
Schubert, D ;
Kreuter, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 57 (02) :369-375
[6]  
Coester CJ, 2000, J MICROENCAPSUL, V17, P187
[7]  
Devereux GS, 2012, ASTHMA, P1
[8]   CROSS-LINKING OF GELATIN CAPSULES AND ITS RELEVANCE TO THEIR IN-VITRO IN-VIVO PERFORMANCE [J].
DIGENIS, GA ;
GOLD, TB ;
SHAH, VP .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (07) :915-921
[9]   Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research [J].
Elzoghby, Ahmed O. .
JOURNAL OF CONTROLLED RELEASE, 2013, 172 (03) :1075-1091
[10]   Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model [J].
Foged, C ;
Brodin, B ;
Frokjaer, S ;
Sundblad, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 298 (02) :315-322